The HCV Quest is a global patient survey, investigating the impact of hepatitis C (HCV) on patients’ personal and social lives, as well as education and work, while also examining patients’ experience of care. The results of the survey, conducted over six months between July and December 2014, have been released in London this morning.
The HCV Quest survey was undertaken by the World Hepatitis Alliance (WHA), with support from the European Association for the Study of the Liver (EASL), with the aim of gathering insights from people living with HCV in order to drive meaningful improvements in its diagnosis and management.
“There is a huge difference in the management of hepatitis C across the world. What the HCV Quest report shows is that a holistic approach is needed. Comprehensive national plans which scale up awareness, prevention and diagnosis and can tackle stigma and discrimination are essential to eliminate the global burden”, said Charles Gore, President of the World Hepatitis Alliance.
Key findings from the survey include:
- Less than 1 in 5 people in Togo, UK, Netherlands, Belarus and Israel were offered a test after describing symptoms of hepatitis C to their physician compared to more than 1 in 2 people in China (69%), Malaysia (66%), Egypt (64%) and Romania (54%).
- Brazil, Argentina and Poland were the least aware of hepatitis C before their diagnosis. Italy, Canada and Greece were the most aware of hepatitis C before their diagnosis.
- Nearly 1 in 4 people have suffered discrimination in work or in education or their prospects have been affected
- 1 in 5 respondents hadn’t told anybody about their condition. In China, 75% of respondents hadn’t told anybody.
The landscape for Australians has changed recently with world leading access to the new direct-acting antiviral medicines. The findings from Australian HCV Quest participants demonstrates just how significant the introduction of the new medicines has been.
You can view the Australian and Global Reports by using the links below.